Delcath Systems Inc (DCTH)vsStryker Corporation (SYK)
DCTH
Delcath Systems Inc
$8.98
-1.32%
HEALTHCARE · Cap: $320.30M
SYK
Stryker Corporation
$327.65
-0.26%
HEALTHCARE · Cap: $125.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 29368% more annual revenue ($25.12B vs $85.23M). SYK leads profitability with a 12.9% profit margin vs 3.2%. SYK appears more attractively valued with a PEG of 1.60. SYK earns a higher WallStSmart Score of 65/100 (C+).
DCTH
Hold44
out of 100
Grade: D
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1879.2%
Fair Value
$0.48
Current Price
$8.98
$8.50 premium
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37.3% year-over-year
Reasonable price relative to book value
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 3.0% — below average capital efficiency
3.2% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DCTH
The strongest argument for DCTH centers on Revenue Growth, Price/Book. Revenue growth of 37.3% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : DCTH
The primary concerns for DCTH are PEG Ratio, Market Cap, Return on Equity. A P/E of 129.6x leaves little room for execution misses. Thin 3.2% margins leave little buffer for downturns.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
DCTH profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.
SYK carries more volatility with a beta of 0.87 — expect wider price swings.
DCTH is growing revenue faster at 37.3% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (65/100 vs 44/100) and 11.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Delcath Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?